Denali Therapeutics Inc (DNLI)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$22.00
Buy
$22.80
$1.50 (+7.15%)
Prices updated at 25 Mar 2026, 21:02 EDT
| Prices minimum 15 mins delay
Prices in USD
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
-
CEO
Dr. Ryan J. Watts, PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
503
Head office
161 Oyster Point Boulevard
South San Francisco
United States
94080
Key personnel
Owner name | Salary |
|---|---|
Mr. Jay T. Flatley Independent Director | 0.07m |
Mr. Julian C. Baker Independent Director | - |
Mr. Peter S. Klein Independent Director | 0.07m |
Dr. David P. Schenkein, M.D. Independent Director | 0.07m |
Mr. Steven E. Krognes, M.B.A. Director | 0.05m |
Mr. Tim Van Hauwermeiren, M. Sc. Director | - |
Dr. Ryan J. Watts, PhD Director, President and Chief Executive Officer | 0.69m |
Dr. Alexander O. Schuth, M.D. Secretary, Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer | 0.54m |
Ms. Jennifer E. Cook Independent Director | 0.06m |
Ms. Nancy A. Thornberry Independent Director | 0.06m |
Dr. Marc Tessier-Lavigne, PhD Independent Director | 0.06m |
Dr. Carole Ho, M.D. Chief Medical Officer and Head of Development | 0.54m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Vanguard Group Inc | 13,057,890 |
| Baillie Gifford & Co Limited. | 12,310,889 |
| BlackRock Inc | 12,289,626 |
| T. Rowe Price Investment Management,Inc. | 8,500,126 |
| Scottish Mortgage Inv Tr | 7,041,240 |
Director dealings
Date | Action |
|---|---|
| 03 Sep 2025 | - |
| 12 Aug 2025 | - |
| 13 Aug 2025 | - |
| 12 Aug 2025 | - |
| 05 Aug 2025 | - |
| 05 Aug 2025 | - |
| 09 Jul 2025 | - |
| 09 Jul 2025 | - |
| 09 Jul 2025 | - |
| 09 Jul 2025 | - |
| 09 Jul 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
| 03 Jun 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
